Teoh Hoon Koon, Chong Pei Pei, Abdullah Maha, Sekawi Zamberi, Tan Geok Chin, Leong Chooi Fun, Cheong Soon Keng
PPUKM-MAKNA Cancer Center, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Cheras, Kuala Lumpur, Malaysia; Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, 43400 UPM, Serdang, Selangor, Malaysia.
Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, 43400 UPM, Serdang, Selangor, Malaysia.
Leuk Res. 2016 Jan;40:44-53. doi: 10.1016/j.leukres.2015.10.004. Epub 2015 Oct 17.
Studies demonstrated that mesenchymal stromal cells (MSC) from bone marrow stroma produced high concentration of interleukin-6 (IL-6) that promoted multiple myeloma cell growth. In view of the failure of IL-6 monoclonal antibody therapy to demonstrate substantial clinical responses in early clinical trials, more effective methods are needed in order to disrupt the favourable microenvironment provided by the bone marrow stroma. In this study, we evaluated the short interfering RNA (siRNA)-mediated silencing of IL-6 in MSC and the efficacy of these genetically modified MSC, with IL-6 suppression, on inhibition of U266 multiple myeloma cell growth. IL-6 mRNA and protein were significantly suppressed by 72h post IL-6 siRNA transfection without affecting the biological properties of MSC. Here we show significant inhibition of cell growth and IL-6 production in U266 cells co-cultured with MSC transfected with IL-6 siRNA when compared to U266 cells co-cultured with control MSC. We also show that the tumour volume and mitotic index of tumours in nude mice co-injected with U266 and MSC transfected with IL-6 siRNA were significantly reduced compared to tumours of mice co-injected with control MSC. Our results suggest potential use of RNA interference mediated therapy for multiple myeloma.
研究表明,来自骨髓基质的间充质基质细胞(MSC)产生高浓度的白细胞介素-6(IL-6),可促进多发性骨髓瘤细胞生长。鉴于IL-6单克隆抗体疗法在早期临床试验中未能显示出显著的临床反应,需要更有效的方法来破坏骨髓基质提供的有利微环境。在本研究中,我们评估了小干扰RNA(siRNA)介导的MSC中IL-6沉默以及这些经基因修饰的、IL-6受抑制的MSC对抑制U266多发性骨髓瘤细胞生长的效果。IL-6 siRNA转染72小时后,IL-6 mRNA和蛋白被显著抑制,且不影响MSC的生物学特性。与用对照MSC共培养的U266细胞相比,我们发现与用IL-6 siRNA转染的MSC共培养的U266细胞的细胞生长和IL-6产生受到显著抑制。我们还表明,与注射对照MSC的小鼠的肿瘤相比,共注射U266和用IL-6 siRNA转染的MSC的裸鼠肿瘤的肿瘤体积和有丝分裂指数显著降低。我们的结果表明RNA干扰介导的疗法在多发性骨髓瘤治疗中具有潜在应用价值。